In-silico Interaction Studies of Quinazoline Derivatives for their Inhibitory Action on Both Wild and Mutant EGFRs
Kaushik S. Hatti, V. Chandregowda, G.Venkateswara Rao, Anil Kush, G.Chandrasekara Reddy*
Vittal Mallya Scientific Research Foundation, P.B.No 406, K.R.Road, Bangalore-560004, INDIA
- *Corresponding Author:
- Dr. G.Chandrasekara Reddy
Vittal Mallya Scientific Research Foundation
P.B.No 406, K.R.Road, Bangalore-560004, INDIA
E-mail: [email protected]
Received Date: February 03, 2009; Accepted Date: March 11, 2009; Published Date: March 12, 2009
Citation: Kaushik SH, Chandregowda V, Venkateswara RG, Anil K, Chandrasekara RG (2009) In-silico Interaction Studies of Quinazoline Derivatives for their Inhibitory Action on Both Wild and Mutant EGFRs. J Proteomics Bioinform 2: 126-130. doi:10.4172/jpb.1000069
Copyright: © 2009 Kaushik SH, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Epidermal growth factor receptor (EGFR) family has gained importance as a target for cancer therapy. However, somatic mutations in the tyrosine kinase domain of EGFR alter its sensitivity to anti-EGFR tyrosine kinase (TK) drugs like gefitinib (IressaTM). Docking studies of a few newly synthesized 6, 7-dialkoxy-4-anilinoquinazoline derivatives which showed EGFR-TK inhibitory activity were conducted. It has been found that the docking energies of these novel quniazolines are comparable with the IC50 values against A431 and MCF-7 tumor cell lines. Though the compounds with benzoxazole (1 & 2) and imidazole side chain (4) exhibited low binding energy to wild-type, but compound 3 had the lowest binding energy to its mutants as well (T790M, L858R and double-mutant). Compounds 1, 2, 4 and gefitinib showed affinity only for selective EGFR variants.